Security key
74587V107
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)
CUSIP: 74587V107
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 29,394,127
- Total 13F value
- $89,648,308
- Share change
- -3,127,041
- Put/Call ratio
- 12%
- SEC-reported price per share
- $3.05
- Number of holders
- 111
- Value change
- -$7,801,084
- Number of buys
- 62
- Number of sells
- 36
- Shares outstanding
- 49,633,071
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
111
Top holders
10
PBYI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
PUMA BIOTECHNOLOGY, INC. SEC filings
PUMA BIOTECHNOLOGY, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74587V107
Recent filing periods:
Ownership snapshot
Top reported holders of PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ACORN BIOVENTURES, L.P.
Disclosed value leader
ACORN BIOVENTURES, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
13F
Lead comparable stake: 8%
13D/G row: ACORN BIOVENTURES, L.P.
Showing 1-6 of 15 holder rows.
Quick read
ACORN BIOVENTURES, L.P. leads the comparable SEC ownership view at 8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ACORN BIOVENTURES, L.P.'s linked filing trail.
Comparable ownership
Top 5
ACORN BIOVENTURES, L.P.
8%
MILLENNIUM MANAGEMENT LLC
3.9%
BlackRock, Inc.
7.7%
VANGUARD GROUP INC
7.3%
Frazier Life Sciences Management,...
6.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
8%
|
$11,859,557
3,940,052 shares
|
+$1,988,442 | 31 Dec 2024 |
| MILLENNIUM MANAGEMENT LLC |
13F
13D/G
Company
|
3.9%
from 13D/G
|
$7,346,264
2,880,888 shares
|
— | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
7.7%
|
$9,759,419
3,827,223 shares
|
— | 30 Sep 2024 |
| VANGUARD GROUP INC |
13F
Company
|
7.3%
|
$9,272,287
3,636,191 shares
|
— | 30 Sep 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
6.2%
|
$7,809,523
3,062,558 shares
|
— | 30 Sep 2024 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
4%
|
$5,017,000
1,968,999 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
111
Shares
29,394,127
Rows available
111
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
100
Q4 2024 holders
111
Holder diff
11
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend